Polaris Market Research has published its latest research report titled Cancer Gene Therapy Market Share, Size, Trends, Industry Analysis Report: By Therapy (Oncolytic Virotherapy, Gene-induced Immunotherapy, and Gene transfer), By Vector Type, By Delivery Approach, By Cancer Type, By End-User, and By Region – Market Forecast, 2026–2034. The report examines the global Cancer Gene Therapy Market , covering its current size, market share, growth prospects, and industry developments. It discusses the factors influencing demand and provides an overview of the changes taking place across the industry.

The study covers the market at global and regional levels. It considers developments in the industry, changing customer requirements, and factors affecting business activity. The research also looks at the challenges faced by market participants and areas where new business opportunities may emerge.

The report draws on primary and secondary research to assess the market. It considers economic conditions, technological developments, regulatory requirements, and other factors relevant to the industry. The findings offer useful information to businesses, investors, and other stakeholders assessing the market.

Market Size and Forecast

The global cancer gene therapy market size was valued at USD 2.51 billion in 2025 and is projected to reach USD 5.70 billion by 2034, growing at a CAGR of 9.60% from 2026 to 2034.

The report includes historical data and future estimates to show how the market is expected to develop during the forecast period.

Market Dynamics

Several factors influence the direction of the Cancer Gene Therapy market. The report considers the following areas to understand their effect on market activity:

Supply and Demand: The report looks at product or service availability and the level of demand in the market. It also considers changes in purchasing requirements and consumption patterns within the sector.

Technological Advancements: The study covers the introduction of new technologies and their effect on existing products, services, and industry practices. It also looks at how technological changes influence product development and market applications.

Regulatory and Legal Environment: The report considers the laws, government policies, and industry standards applicable to the Cancer Gene Therapy market. It also looks at how regulatory changes affect companies and their operations.

Economic Factors: The study takes into account economic conditions such as inflation, interest rates, income levels, and economic growth. These factors are considered in relation to their influence on demand and investment in the market.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/cancer-gene-therapy-market

Key Market Trends

The report highlights important developments in the Cancer Gene Therapy market. It looks at changes in customer preferences, product offerings, industry practices, and the adoption of new technologies. The discussion also covers recent developments that may influence market demand and business decisions.

The study considers how these changes are affecting market participants and their approach to product development, business expansion, and customer requirements.

Competitive Landscape

The report identifies the major companies operating in the Cancer Gene Therapy market. It provides an overview of their business operations, product or service offerings, and market presence. The study also covers recent company developments and strategies used to strengthen their positions.

These strategies may include product launches, partnerships, mergers and acquisitions, research and development, and geographical expansion. A SWOT analysis of major market participants is also included. The report discusses potential entry barriers and other challenges that may affect competition.

Some of the key market players include:

• Adaptimmune Limited (US WorldMeds)
• Alaunos Therapeutics, Inc.
• Amgen Inc.
• Bristol Myers Squibb Company
• CARsgen Therapeutics
• Genelux Corporation (Develops oncolytic immunotherapies including Olvi-Vec)
• Genetix Biotherapeutics
• Gilead Sciences, Inc. (Kite Pharma)
• GlaxoSmithKline plc (Commercial owner of Imlygic, an oncolytic viral therapy for melanoma lesions)
• JW Therapeutics
• Krystal Biotech, Inc.
• Legend Biotech
• Nanjing IASO Biotechnology
• Novartis AG (Commercial CAR-T owner of Kymriah and an active cell-and-gene therapy participant)
• Orchard Therapeutics (a Kyowa Kirin company)

Market Segmentation

By Therapy

• Oncolytic Virotherapy
• Gene-induced Immunotherapy
• Gene transfer

By Vector Type

• Lentivirus
• RetroVirus & gamma RetroVirus
• AAV
• Modified Herpes Simplex Virus
• Adenovirus
• Others

By Delivery Approach

• Ex Vivo
• In Vivo

By Cancer Type

• Hematologic Malignancies
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
• Solid Tumors
  • Breast Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Colon Cancer
  • Skin cancer

By End-User

• Hospitals
• Research Institutes
• Biopharma Companies
• Diagnostic centers
• Others

The Report Answers Questions Such As

• What is the current size of the global Cancer Gene Therapy market?
• What is the projected market size by the end of the forecast period?
• What CAGR is expected during the forecast period?
• What factors are influencing market growth?
• What are the major trends shaping the industry?
• Which segment accounts for the largest market share?
• Which segment is expected to grow at the fastest rate?
• Which region holds the largest market share?
• Who are the leading companies operating in the market?
• What opportunities are available to existing and new market participants?

More Trending Latest Reports By Polaris Market Research:

5G Infrastructure Market Size

Sleep Disorders Market Share

5G Enterprise Market Growth

5G System Integration Market Forecast

Air Fryer Market Analysis

Autonomous Trucks Market Opportunities

Autonomous Underwater Vehicle Market Trends

Cancer Or Tumor Profiling Market Size

5G Iot Market Share

Dairy Enzymes Market Growth